Abstract 164P
Background
Molecularly-matched therapy (MMT) is associated with increased response rates and in some cases with improved survival. Next generation sequencing (NGS) - based multigene panels offer a wide range of analyzed markers. There is a need to optimize comprehensive profiling and find the most relevant molecular targets according to tumor type.
Methods
Retrospective analysis of NGS reports and clinical data of patients with advanced gastrointestinal tumors was performed. The frequency of detected molecular alterations in each cancer type, the frequency of MMT recommendation were assessed. Efficacy was estimated using progression-free survival (PFS) ratio (PFS2/PFS1).
Results
Between 2019 and 2023, tumor samples from 107 patients with gastrointestinal tumors were analyzed using NGS-based panels (colorectal cancer (CRC) - 64 patients (59%), pancreatic cancer (PCa) - 21 (20%), cholangiocellular cancer (CCC) - 12 (11%), gastric cancer (GC) - 11 (10%). Median age was 58 years, median number of lines before analysis - 2. MMT after NGS was administered to 17 patients (16%). Of these patients 6 samples were assesed as ESCAT I tier (35%), 2 (12%) - ESCAT IIB, 2 (12%) - ESCAT IIIA, 7 (51%) - ESCAT IIIB. PFS2/1 ratio≥1,3 was reached in 10 patients (59%). In the cohort of patients who have not been prescribed MMT, the PFS ratio was available for 42 patients, among whom 11 patients (26%) achieved PFS1/2 ≥1,3 (p=0,005). MMT was the only favorable predictor of PFS2/1 ≥1.3 (HR 0.13; 95% CI 0.03 - 0.50, p=0.003) in univariate analysis. Median overall survival in the MMT and non-MMT groups was 6 and 5 months, respectively (HR=2.07; 95% CI 1.01 - 4.26). Table: 164P
Variables | Univariate analysis | |
HR (95% CI) | p value | |
Age, years ≥60 <60 | 1,00 0,80 (0,21 -2,91) | 0,72 |
Number of lines before analysis, ≤1 ≥2 | 1,00 0,67 (0,16 - 2,86) | 0,59 |
Sex, m f | 1,60 (0,45 - 5,70) 1,00 | 0,47 |
Molecular tumor board Yes No | 1,00 0,61 (0,13 - 2,85) | 0,53 |
RAS RASwt RASmut | 1,00 (0,28 - 3,61) 1,00 | 1,00 |
MMT Yes No | 1,00 0,13 (0,03 - 0,50) | 0,003 |
Conclusions
MMT may potentially have advantages over non-MMT in advanced gastrointestinal cancers when standard therapy options are limited. In order to optimize testing in routine practice, it is necessary to create more limited panels for profiling according to each tumor type.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract